Kyra Denise Zens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kyra Denise Zens has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Christian Münz
Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland
9 shared publications - Phung Lang
University of Zürich, Epidemiology, Biostatistics and Prevention Institute, Switzerland
9 shared publications - Jan Fehr
Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
6 shared publications - Dominik Menges
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
5 shared publications - Donna L. Farber
Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, USA
5 shared publications - Milo Alan Puhan
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
5 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (4) , e004710
HPV vaccination uptake and schedule completion among adults aged 18–45 in Switzerland: a nationwide cross-sectional study
- 1 October 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (4) , e004710
Open AccessHPV vaccination uptake and schedule completion among adults aged 18–45 in Switzerland: a nationwide cross-sectional study
- Open Access
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Estimating Tick-Borne Encephalitis Risk among Unvaccinated Adults and Total Infection Burden in Switzerland, 2017-2021
Background: Tick-borne encephalitis (TBE) is a severe but vaccine-preventable viral infection of the central nervous system. Reported incidence does not fully capture TBE risk among unvaccinated individuals or the burden of TBE virus (TBEV) infections. To address this, we estimated TBE incidence among unvaccinated adults and TBEV infections compared with reported cases. Methods: We combined TBE surveillance data, vaccination coverage and vaccine effectiveness (VE) estimates, and published and newly generated serological data. The primary surveillance period was 2017-2021. Incidence among unvaccinated adults (IUV) was estimated by adjusting reported incidence for vaccination coverage and VE. Infection hazard (IH) was estimated from seroprevalence and seroreversion using a reversible catalytic model, and clinical fraction was calculated as IUV divided by IH. Findings: Between 2017 and 2021, an average of 268 TBE cases per year were reported among adults aged 18-79 years in Switzerland. After adjustment for vaccination, IUV was 6.56 per 100,000, exceeding the WHO “highly endemic” threshold. In Zurich, 9.9% (15/151) of adults without documented TBEV, JEV, or YFV vaccination were seropositive or borderline for TBEV-specific IgG. Across seven included cantons, pooled IH was 1.60% per year, corresponding to an estimated 10-year infection risk of approximately 15%; pooled clinical fraction was 0.50%, corresponding to approximately 200 infections per reported case. Interpretation: Reported TBE incidence substantially underestimates both disease risk among unvaccinated adults as well as total TBEV infection burden in Switzerland. Accounting for vaccination coverage, VE, and antibody seroreversion provides a more complete basis for interpreting TBE risk.
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEstimating Tick-Borne Encephalitis Risk among Unvaccinated Adults and Total Infection Burden in Switzerland, 2017-2021
Background: Tick-borne encephalitis (TBE) is a severe but vaccine-preventable viral infection of the central nervous system. Reported incidence does not fully capture TBE risk among unvaccinated individuals or the burden of TBE virus (TBEV) infections. To address this, we estimated TBE incidence among unvaccinated adults and TBEV infections compared with reported cases. Methods: We combined TBE surveillance data, vaccination coverage and vaccine effectiveness (VE) estimates, and published and newly generated serological data. The primary surveillance period was 2017-2021. Incidence among unvaccinated adults (IUV) was estimated by adjusting reported incidence for vaccination coverage and VE. Infection hazard (IH) was estimated from seroprevalence and seroreversion using a reversible catalytic model, and clinical fraction was calculated as IUV divided by IH. Findings: Between 2017 and 2021, an average of 268 TBE cases per year were reported among adults aged 18-79 years in Switzerland. After adjustment for vaccination, IUV was 6.56 per 100,000, exceeding the WHO “highly endemic” threshold. In Zurich, 9.9% (15/151) of adults without documented TBEV, JEV, or YFV vaccination were seropositive or borderline for TBEV-specific IgG. Across seven included cantons, pooled IH was 1.60% per year, corresponding to an estimated 10-year infection risk of approximately 15%; pooled clinical fraction was 0.50%, corresponding to approximately 200 infections per reported case. Interpretation: Reported TBE incidence substantially underestimates both disease risk among unvaccinated adults as well as total TBEV infection burden in Switzerland. Accounting for vaccination coverage, VE, and antibody seroreversion provides a more complete basis for interpreting TBE risk.
- Open Access
- 27 April 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (2) , e004208
Human papillomavirus vaccine uptake and the impact of school-based health services in Switzerland: a cross-sectional study
Introduction: Human papillomavirus (HPV) is a major cause of cervical cancer and other related diseases. Switzerland has implemented a national HPV immunisation strategy since 2007. This study examined trends in HPV vaccination coverage and valid schedule completion among adolescents in Switzerland between 2008 and 2022 and assessed differences in vaccination outcomes by delivery through school health services. Methods: We analysed data from the Swiss National Vaccination Coverage Survey, including 46 914 sampled adolescents, of whom 32 554 provided vaccination documentation. The analysis included 16-year-old girls (2008–2022) and 16-year-old boys (2017–2022). Vaccination uptake (≥1, ≥2 and ≥3 doses) and valid schedule completion (valid two-dose, valid three-dose and valid total) were estimated using weighted proportions with 95% CIs. Differences between cantons with and without HPV vaccination delivered through school health services were assessed for the 2017–2019 survey period. Multivariable logistic regression was used to evaluate factors associated with valid total schedule completion among girls (2011–2019). Results: Vaccination coverage among 16-year-old girls increased from 28.8% (95% CI 24.4% to 33.2%) in the survey period 2008–2010 to 74.6% (95% CI 72.2% to 77%) in the survey period 2020–2022 for ≥1 dose. Valid schedule completion rose substantially, particularly for the two-dose regimen after the 2012 recommendation change. Among boys, coverage reached 51.2% (95% CI 48.4% to 54%) for ≥1 dose in the survey period 2020–2022. In 2017–2019, completion of a valid HPV schedule among girls was 51.8% (95% CI 48.6% to 54.9%) in cantons with school health services versus 40.8% (95% CI 37.2% to 44.5%) in those without such services. In multivariable analyses, school health services, urban residence and French-speaking region were associated with higher odds of valid schedule completion. Conclusion: HPV vaccination coverage in Switzerland has improved over time, particularly following the introduction of the two-dose schedule. Delivery through school health services was associated with higher coverage and completion, highlighting the importance of organised vaccination delivery strategies.
- 27 April 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (2) , e004208
Open AccessHuman papillomavirus vaccine uptake and the impact of school-based health services in Switzerland: a cross-sectional study
Introduction: Human papillomavirus (HPV) is a major cause of cervical cancer and other related diseases. Switzerland has implemented a national HPV immunisation strategy since 2007. This study examined trends in HPV vaccination coverage and valid schedule completion among adolescents in Switzerland between 2008 and 2022 and assessed differences in vaccination outcomes by delivery through school health services. Methods: We analysed data from the Swiss National Vaccination Coverage Survey, including 46 914 sampled adolescents, of whom 32 554 provided vaccination documentation. The analysis included 16-year-old girls (2008–2022) and 16-year-old boys (2017–2022). Vaccination uptake (≥1, ≥2 and ≥3 doses) and valid schedule completion (valid two-dose, valid three-dose and valid total) were estimated using weighted proportions with 95% CIs. Differences between cantons with and without HPV vaccination delivered through school health services were assessed for the 2017–2019 survey period. Multivariable logistic regression was used to evaluate factors associated with valid total schedule completion among girls (2011–2019). Results: Vaccination coverage among 16-year-old girls increased from 28.8% (95% CI 24.4% to 33.2%) in the survey period 2008–2010 to 74.6% (95% CI 72.2% to 77%) in the survey period 2020–2022 for ≥1 dose. Valid schedule completion rose substantially, particularly for the two-dose regimen after the 2012 recommendation change. Among boys, coverage reached 51.2% (95% CI 48.4% to 54%) for ≥1 dose in the survey period 2020–2022. In 2017–2019, completion of a valid HPV schedule among girls was 51.8% (95% CI 48.6% to 54.9%) in cantons with school health services versus 40.8% (95% CI 37.2% to 44.5%) in those without such services. In multivariable analyses, school health services, urban residence and French-speaking region were associated with higher odds of valid schedule completion. Conclusion: HPV vaccination coverage in Switzerland has improved over time, particularly following the introduction of the two-dose schedule. Delivery through school health services was associated with higher coverage and completion, highlighting the importance of organised vaccination delivery strategies.
- Open Access
- 10 November 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (11) , e70083
Not Just Passing Through: Bone Marrow as a Home for Diverse Resident T Cells
Recent studies add to our understanding of T cell residency in the human bone marrow (BM). In the May 2025 issue of EJI, Schneider Revueltas et al. demonstrate that CD69 − CD4 + and CD8+ memory T cells, presumed to be recirculating, have a distinct transcriptional cluster profile and a distinct TCR repertoire from their blood counterparts. These findings are in line with CD69 − memory T cells taking up residence in the BM, similar to their CD69 + counterparts. In parallel, Pulvirenti et al. identify a subset of CD69 + EOMES + GzmK + Tr1‐like cells in the BM maintained by IL‐15. Together, these studies refine our understanding of the BM as a heterogeneous immune niche and suggest a broader definition of resident cells within this tissue.
- 10 November 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (11) , e70083
Open AccessNot Just Passing Through: Bone Marrow as a Home for Diverse Resident T Cells
Recent studies add to our understanding of T cell residency in the human bone marrow (BM). In the May 2025 issue of EJI, Schneider Revueltas et al. demonstrate that CD69 − CD4 + and CD8+ memory T cells, presumed to be recirculating, have a distinct transcriptional cluster profile and a distinct TCR repertoire from their blood counterparts. These findings are in line with CD69 − memory T cells taking up residence in the BM, similar to their CD69 + counterparts. In parallel, Pulvirenti et al. identify a subset of CD69 + EOMES + GzmK + Tr1‐like cells in the BM maintained by IL‐15. Together, these studies refine our understanding of the BM as a heterogeneous immune niche and suggest a broader definition of resident cells within this tissue.
- Open Access
Fast-Track to Protection? A Review of Encepur’s Express Dosing Schedule for Tick-Borne Encephalitis
Cases of confirmed tick-borne encephalitis (TBE) have increased dramatically over the last 30 years, highlighting growing endemicity across Eurasia. Two preventative vaccines, Encepur® (Bavarian Nordic A/S, Hellerup, Denmark) and FSME-Immun® (Pfizer Ireland Pharmaceuticals, Cork, Ireland), are licensed in Europe. For both vaccines, primary immunisation consists of a three-dose regimen, administered over approximately one year using “Conventional” dosing schedules. Both vaccines can also be administered using “Rapid” schedules, which shorten the interval between the first two doses but still take around a year to complete. Currently, only Encepur offers an approved “Express” schedule, whereby all three priming doses are given within 21 days. The effectiveness of TBE vaccination is markedly higher in individuals who receive ≥3 doses, compared with those who receive only one or two doses, indicating the importance of series completion. Moreover, seropositivity takes several weeks to develop after vaccination. As such, individuals are advised to initiate vaccination before peak tick season to allow sufficient time to develop protective immunity during periods of highest risk. Despite these considerations, vaccine uptake and series completion remain suboptimal in TBE-endemic regions. Furthermore, many vaccinees—including travellers with limited time before departure and residents of endemic areas—do not initiate vaccination until peak tick season, when risk is greatest. Broader use of Encepur’s Express schedule may help to address these challenges. The Express schedule’s 21-day timeframe may help to increase series completion by reducing drop-offs associated with prolonged dosing intervals. Additionally, it can support timely protection by enabling series completion, with sufficient time post-vaccination to develop protective immunity, all within a single-risk season, even among late initiators. In this narrative review, we evaluate the safety and immunogenicity of Encepur’s Express schedule and discuss its potential utility across a broader range of vaccinees. These insights may help inform TBE vaccine recommendations and support efforts towards improving vaccination strategies amid increasing TBE risk.
Open AccessFast-Track to Protection? A Review of Encepur’s Express Dosing Schedule for Tick-Borne Encephalitis
Cases of confirmed tick-borne encephalitis (TBE) have increased dramatically over the last 30 years, highlighting growing endemicity across Eurasia. Two preventative vaccines, Encepur® (Bavarian Nordic A/S, Hellerup, Denmark) and FSME-Immun® (Pfizer Ireland Pharmaceuticals, Cork, Ireland), are licensed in Europe. For both vaccines, primary immunisation consists of a three-dose regimen, administered over approximately one year using “Conventional” dosing schedules. Both vaccines can also be administered using “Rapid” schedules, which shorten the interval between the first two doses but still take around a year to complete. Currently, only Encepur offers an approved “Express” schedule, whereby all three priming doses are given within 21 days. The effectiveness of TBE vaccination is markedly higher in individuals who receive ≥3 doses, compared with those who receive only one or two doses, indicating the importance of series completion. Moreover, seropositivity takes several weeks to develop after vaccination. As such, individuals are advised to initiate vaccination before peak tick season to allow sufficient time to develop protective immunity during periods of highest risk. Despite these considerations, vaccine uptake and series completion remain suboptimal in TBE-endemic regions. Furthermore, many vaccinees—including travellers with limited time before departure and residents of endemic areas—do not initiate vaccination until peak tick season, when risk is greatest. Broader use of Encepur’s Express schedule may help to address these challenges. The Express schedule’s 21-day timeframe may help to increase series completion by reducing drop-offs associated with prolonged dosing intervals. Additionally, it can support timely protection by enabling series completion, with sufficient time post-vaccination to develop protective immunity, all within a single-risk season, even among late initiators. In this narrative review, we evaluate the safety and immunogenicity of Encepur’s Express schedule and discuss its potential utility across a broader range of vaccinees. These insights may help inform TBE vaccine recommendations and support efforts towards improving vaccination strategies amid increasing TBE risk.
- Open Access
- 1 September 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (9) , 4207
Longitudinal characterisation of immune responses in blood and breast milk and symptoms after mRNA vaccination in lactating women
BACKGROUND: Pregnant and lactating women were systematically excluded from the first SARS-CoV-2 vaccine trials, leading to great uncertainty in those women and their treating clinicians concerning the safety of the SARS-CoV-2 vaccine [1]. Detailed information about the immune response in blood and breast milk of lactating women and the transmission to infants after mRNA vaccination against SARS-CoV-2 is still scarce. STUDY AIMS: We aimed to characterise the antibody responses and neutralising antibody responses against different variants of SARS-CoV-2 after mRNA vaccination in blood and breast milk of lactating women. We further aimed to compare the antibody responses to a matched cohort of non-lactating women, and to identify factors associated with antibody responses. Additionally, we assessed the occurrence of post-vaccination symptoms, health status trajectories and SARS-CoV-2 infections among participants and their infants after vaccination. METHODS: We conducted a single-centre prospective cohort study recruiting participants between October 2021 and February 2022. The study participants were recruited directly on-site at the reference vaccination centre of the Canton of Zurich, or referred to the study centre by external healthcare providers. Eligible participants were aged >18 years and had not previously been vaccinated against SARS-CoV-2 with an mRNA vaccine. The primary outcome was the antibody response (anti-S IgA, anti-S IgG, anti-N IgG) in blood plasma and breast milk in lactating women at baseline, 4 weeks and 6 weeks. Secondary outcomes were neutralising antibody responses in blood plasma at 6 weeks, as well as self-reported post-vaccination symptoms, health status (assessed using the EuroQol visual analogue scale [EQ VAS]) and SARS-CoV-2 infections in mothers and infants over the study follow-up. Antibody responses in plasma were compared with a propensity score-matched sample of non-lactating women from the population-based Zurich SARS-CoV-2 Vaccination Cohort. Descriptive statistical analyses were conducted for all outcomes, and associations between demographic and clinical factors with antibody responses were evaluated using multivariable mixed linear regression models. RESULTS: Of 45 eligible study participants, 40 lactating women completed at least two immunological assessments and were included in analyses. Study participants had a mean age of 34.9 years and 5 (12.8%, 5/39) participants reported a prior SARS-CoV-2 infection.Two weeks after the second vaccination (at 6 weeks), all study participants tested seropositive in blood plasma for anti-S IgG and anti-S IgA, with 3 (7.7%, 3/39) testing seropositive for anti-N IgG. Neutralising antibodies against the wildtype, delta and omicron variants were detected in blood plasma of 100% (40/40), 97.4% (39/40) and 64.1% (26/40) of participants, respectively. All breast milk samples tested positive for anti-S IgG, but only 15.6% (6/40) showed detectable anti-S IgA levels. Antibody responses were similar in the matched cohort of non-lactating women. Of the 136 post-vaccination symptoms reported in mothers and the 37 reported in infants (173 post-vaccination symptoms in total), the majority were reported to be of very mild to medium severity (87.1%, 108/124 in mothers; 93.5%, 29/31 in infants) and resolved spontaneously (70.7%, 70/99 in lactating women; 42.3%, 11/26 in infants). EQ VAS scores were high at baseline (median: 85, interquartile range [IQR]: 75.5–92) and showed a minimal decrease at weeks 4 and 6 (medians: 82 and 81), with self-reported wellbeing returning to baseline levels by month 6. Over six months, 52% of the study participants reached for full follow-up (13/25) reported an infection with SARS-CoV-2, all of mild severity. CONCLUSIONS: Antibody responses against SARS-CoV-2 in blood plasma and breast milk were found to be anti-S IgG-dominant, and neutralisation assays at 6 months showed high neutralisation capacity for the wildtype and delta variants in plasma. No difference between lactating and non-lactating women was found. Self-reported post-vaccination symptoms were mostly of medium severity, and health status returned to baseline levels by 6 months after a short-term decrease around 4–6 weeks. Mild infections were reported after vaccination.
- 1 September 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (9) , 4207
Open AccessLongitudinal characterisation of immune responses in blood and breast milk and symptoms after mRNA vaccination in lactating women
BACKGROUND: Pregnant and lactating women were systematically excluded from the first SARS-CoV-2 vaccine trials, leading to great uncertainty in those women and their treating clinicians concerning the safety of the SARS-CoV-2 vaccine [1]. Detailed information about the immune response in blood and breast milk of lactating women and the transmission to infants after mRNA vaccination against SARS-CoV-2 is still scarce. STUDY AIMS: We aimed to characterise the antibody responses and neutralising antibody responses against different variants of SARS-CoV-2 after mRNA vaccination in blood and breast milk of lactating women. We further aimed to compare the antibody responses to a matched cohort of non-lactating women, and to identify factors associated with antibody responses. Additionally, we assessed the occurrence of post-vaccination symptoms, health status trajectories and SARS-CoV-2 infections among participants and their infants after vaccination. METHODS: We conducted a single-centre prospective cohort study recruiting participants between October 2021 and February 2022. The study participants were recruited directly on-site at the reference vaccination centre of the Canton of Zurich, or referred to the study centre by external healthcare providers. Eligible participants were aged >18 years and had not previously been vaccinated against SARS-CoV-2 with an mRNA vaccine. The primary outcome was the antibody response (anti-S IgA, anti-S IgG, anti-N IgG) in blood plasma and breast milk in lactating women at baseline, 4 weeks and 6 weeks. Secondary outcomes were neutralising antibody responses in blood plasma at 6 weeks, as well as self-reported post-vaccination symptoms, health status (assessed using the EuroQol visual analogue scale [EQ VAS]) and SARS-CoV-2 infections in mothers and infants over the study follow-up. Antibody responses in plasma were compared with a propensity score-matched sample of non-lactating women from the population-based Zurich SARS-CoV-2 Vaccination Cohort. Descriptive statistical analyses were conducted for all outcomes, and associations between demographic and clinical factors with antibody responses were evaluated using multivariable mixed linear regression models. RESULTS: Of 45 eligible study participants, 40 lactating women completed at least two immunological assessments and were included in analyses. Study participants had a mean age of 34.9 years and 5 (12.8%, 5/39) participants reported a prior SARS-CoV-2 infection.Two weeks after the second vaccination (at 6 weeks), all study participants tested seropositive in blood plasma for anti-S IgG and anti-S IgA, with 3 (7.7%, 3/39) testing seropositive for anti-N IgG. Neutralising antibodies against the wildtype, delta and omicron variants were detected in blood plasma of 100% (40/40), 97.4% (39/40) and 64.1% (26/40) of participants, respectively. All breast milk samples tested positive for anti-S IgG, but only 15.6% (6/40) showed detectable anti-S IgA levels. Antibody responses were similar in the matched cohort of non-lactating women. Of the 136 post-vaccination symptoms reported in mothers and the 37 reported in infants (173 post-vaccination symptoms in total), the majority were reported to be of very mild to medium severity (87.1%, 108/124 in mothers; 93.5%, 29/31 in infants) and resolved spontaneously (70.7%, 70/99 in lactating women; 42.3%, 11/26 in infants). EQ VAS scores were high at baseline (median: 85, interquartile range [IQR]: 75.5–92) and showed a minimal decrease at weeks 4 and 6 (medians: 82 and 81), with self-reported wellbeing returning to baseline levels by month 6. Over six months, 52% of the study participants reached for full follow-up (13/25) reported an infection with SARS-CoV-2, all of mild severity. CONCLUSIONS: Antibody responses against SARS-CoV-2 in blood plasma and breast milk were found to be anti-S IgG-dominant, and neutralisation assays at 6 months showed high neutralisation capacity for the wildtype and delta variants in plasma. No difference between lactating and non-lactating women was found. Self-reported post-vaccination symptoms were mostly of medium severity, and health status returned to baseline levels by 6 months after a short-term decrease around 4–6 weeks. Mild infections were reported after vaccination.
- Open Access
- 22 October 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (20)
Epstein-Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues
EBV contributes to around 2% of all tumors worldwide. Simultaneously, more than 90% of healthy human adults persistently carry EBV without clinical symptoms. In most EBV carriers, it is thought that virus-induced tumorigenesis is prevented by cell-mediated immunity. Specifically, memory CD8 + T cells recognize EBV-infected cells during latent and lytic infection. Using a symptomatic primary infection model, similar to infectious mononucleosis (IM), we found EBV-induced CD8 + tissue resident memory T cells (TRMs) in mice with a humanized immune system. These human TRMs were preferentially established after intranasal EBV infection in nasal-associated lymphoid tissues (NALT), equivalent to tonsils, the primary site of EBV infection in humans. They expressed canonical TRM markers, including CD69, CD103, and BLIMP-1, as well as granzyme B, CD107a, and CCL5. Despite cytotoxic activity and cytokine production ex vivo, these TRMs demonstrated reduced CD27 expression and proliferation and failed to control EBV viral loads in the NALT during infection, although effector memory T cells (TEMs) controlled viral titers in spleen and blood. Overall, TRMs are established in mucosal lymphoid tissues by EBV infection, but primarily, systemic CD8 + T cell expansion seems to control viral loads in the context of IM-like infection.
- 22 October 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (20)
Open AccessEpstein-Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues
EBV contributes to around 2% of all tumors worldwide. Simultaneously, more than 90% of healthy human adults persistently carry EBV without clinical symptoms. In most EBV carriers, it is thought that virus-induced tumorigenesis is prevented by cell-mediated immunity. Specifically, memory CD8 + T cells recognize EBV-infected cells during latent and lytic infection. Using a symptomatic primary infection model, similar to infectious mononucleosis (IM), we found EBV-induced CD8 + tissue resident memory T cells (TRMs) in mice with a humanized immune system. These human TRMs were preferentially established after intranasal EBV infection in nasal-associated lymphoid tissues (NALT), equivalent to tonsils, the primary site of EBV infection in humans. They expressed canonical TRM markers, including CD69, CD103, and BLIMP-1, as well as granzyme B, CD107a, and CCL5. Despite cytotoxic activity and cytokine production ex vivo, these TRMs demonstrated reduced CD27 expression and proliferation and failed to control EBV viral loads in the NALT during infection, although effector memory T cells (TEMs) controlled viral titers in spleen and blood. Overall, TRMs are established in mucosal lymphoid tissues by EBV infection, but primarily, systemic CD8 + T cell expansion seems to control viral loads in the context of IM-like infection.
- Open Access
- 15 June 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-14
Effects of Pycnogenol® in people with post-COVID-19 condition (PYCNOVID): study protocol for a single-center, placebo controlled, quadruple-blind, randomized trial
Background: A significant proportion of the global population has been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at some point since the onset of the pandemic. Although most individuals who develop coronavirus disease 2019 (COVID-19) recover without complications, about 6% have persistent symptoms, referred to as post-COVID-19 condition (PCC). Intervention studies investigating treatments that potentially alleviate PCC-related symptoms and thus aim to mitigate the global public health burden and healthcare costs linked to PCC are desperately needed. The PYCNOVID trial investigates the effects of Pycnogenol®, a French maritime pine bark extract with anti-inflammatory and antioxidative properties, versus placebo on patient-reported health status in people with PCC. Methods: This is a single-center, placebo-controlled, quadruple blind, randomized trial. We aim to randomly assign 150 individuals with PCC (1:1 ratio) to receive either 200 mg Pycnogenol® or placebo daily for 12 weeks. Randomization is stratified for duration of PCC symptoms (≤ 6 months versus > 6 months) and presence of symptomatic chronic disease(s). The primary endpoint is perceived health status at 12 weeks (EuroQol—Visual Analogue Scale) adjusted for baseline values and stratification factors. Secondary endpoints include change in self-reported PCC symptoms, health-related quality of life, symptoms of depression and anxiety, cognitive function, functional exercise capacity, physical activity measured with accelerometry, and blood biomarkers for endothelial health, inflammation, coagulation, platelet function, and oxidative stress. Investigators, study participants, outcome assessors, and data analysts are blinded regarding the intervention assignment. Individuals with PCC were involved in the design of this study. Discussion: This is the first trial to investigate the effects of Pycnogenol® versus placebo on patient-reported health status in people with PCC. Should the trial proof clinical effectiveness, Pycnogenol® may serve as a therapeutic approach to mitigate symptoms associated with PCC. Trial registration: The study is registered at ClinicalTrials.gov. :NCT05890534, June 6, 2023.
- 15 June 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-14
Open AccessEffects of Pycnogenol® in people with post-COVID-19 condition (PYCNOVID): study protocol for a single-center, placebo controlled, quadruple-blind, randomized trial
Background: A significant proportion of the global population has been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at some point since the onset of the pandemic. Although most individuals who develop coronavirus disease 2019 (COVID-19) recover without complications, about 6% have persistent symptoms, referred to as post-COVID-19 condition (PCC). Intervention studies investigating treatments that potentially alleviate PCC-related symptoms and thus aim to mitigate the global public health burden and healthcare costs linked to PCC are desperately needed. The PYCNOVID trial investigates the effects of Pycnogenol®, a French maritime pine bark extract with anti-inflammatory and antioxidative properties, versus placebo on patient-reported health status in people with PCC. Methods: This is a single-center, placebo-controlled, quadruple blind, randomized trial. We aim to randomly assign 150 individuals with PCC (1:1 ratio) to receive either 200 mg Pycnogenol® or placebo daily for 12 weeks. Randomization is stratified for duration of PCC symptoms (≤ 6 months versus > 6 months) and presence of symptomatic chronic disease(s). The primary endpoint is perceived health status at 12 weeks (EuroQol—Visual Analogue Scale) adjusted for baseline values and stratification factors. Secondary endpoints include change in self-reported PCC symptoms, health-related quality of life, symptoms of depression and anxiety, cognitive function, functional exercise capacity, physical activity measured with accelerometry, and blood biomarkers for endothelial health, inflammation, coagulation, platelet function, and oxidative stress. Investigators, study participants, outcome assessors, and data analysts are blinded regarding the intervention assignment. Individuals with PCC were involved in the design of this study. Discussion: This is the first trial to investigate the effects of Pycnogenol® versus placebo on patient-reported health status in people with PCC. Should the trial proof clinical effectiveness, Pycnogenol® may serve as a therapeutic approach to mitigate symptoms associated with PCC. Trial registration: The study is registered at ClinicalTrials.gov. :NCT05890534, June 6, 2023.
- Open Access
- 2 May 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (18) , 2300558
A combined cross-sectional analysis and case-control study evaluating tick-borne encephalitis vaccination coverage, disease and vaccine effectiveness in children and adolescents, Switzerland, 2005 to 2022
Background: Tick-borne encephalitis (TBE) is a severe, vaccine-preventable viral infection of the central nervous system. Symptoms are generally milder in children and adolescents than in adults, though severe disease does occur. A better understanding of the disease burden and duration of vaccine-mediated protection is important for vaccination recommendations. Aim: To estimate TBE vaccination coverage, disease severity and vaccine effectiveness (VE) among individuals aged 0–17 years in Switzerland. Methods: Vaccination coverage between 2005 and 2022 was estimated using the Swiss National Vaccination Coverage Survey (SNVCS), a nationwide, repeated cross-sectional study assessing vaccine uptake. Incidence and severity of TBE between 2005 and 2022 were determined using data from the Swiss disease surveillance system and VE was calculated using a case–control analysis, matching TBE cases with SNVCS controls. Results: Over the study period, vaccination coverage increased substantially, from 4.8% (95% confidence interval (CI): 4.1–5.5%) to 50.1% (95% CI: 48.3–52.0%). Reported clinical symptoms in TBE cases were similar irrespective of age. Neurological involvement was less likely in incompletely (1–2 doses) and completely (≥ 3 doses) vaccinated cases compared with unvaccinated ones. For incomplete vaccination, VE was 66.2% (95% CI: 42.3–80.2), whereas VE for complete vaccination was 90.8% (95% CI: 87.7–96.4). Vaccine effectiveness remained high, 83.9% (95% CI: 69.0–91.7) up to 10 years since last vaccination. Conclusions: Even children younger than 5 years can experience severe TBE. Incomplete and complete vaccination protect against neurological manifestations of the disease. Complete vaccination offers durable protection up to 10 years against TBE.
- 2 May 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (18) , 2300558
Open AccessA combined cross-sectional analysis and case-control study evaluating tick-borne encephalitis vaccination coverage, disease and vaccine effectiveness in children and adolescents, Switzerland, 2005 to 2022
Background: Tick-borne encephalitis (TBE) is a severe, vaccine-preventable viral infection of the central nervous system. Symptoms are generally milder in children and adolescents than in adults, though severe disease does occur. A better understanding of the disease burden and duration of vaccine-mediated protection is important for vaccination recommendations. Aim: To estimate TBE vaccination coverage, disease severity and vaccine effectiveness (VE) among individuals aged 0–17 years in Switzerland. Methods: Vaccination coverage between 2005 and 2022 was estimated using the Swiss National Vaccination Coverage Survey (SNVCS), a nationwide, repeated cross-sectional study assessing vaccine uptake. Incidence and severity of TBE between 2005 and 2022 were determined using data from the Swiss disease surveillance system and VE was calculated using a case–control analysis, matching TBE cases with SNVCS controls. Results: Over the study period, vaccination coverage increased substantially, from 4.8% (95% confidence interval (CI): 4.1–5.5%) to 50.1% (95% CI: 48.3–52.0%). Reported clinical symptoms in TBE cases were similar irrespective of age. Neurological involvement was less likely in incompletely (1–2 doses) and completely (≥ 3 doses) vaccinated cases compared with unvaccinated ones. For incomplete vaccination, VE was 66.2% (95% CI: 42.3–80.2), whereas VE for complete vaccination was 90.8% (95% CI: 87.7–96.4). Vaccine effectiveness remained high, 83.9% (95% CI: 69.0–91.7) up to 10 years since last vaccination. Conclusions: Even children younger than 5 years can experience severe TBE. Incomplete and complete vaccination protect against neurological manifestations of the disease. Complete vaccination offers durable protection up to 10 years against TBE.
- Open Access
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1352720
Defining the “Correlate(s) of Protection” to tick-borne encephalitis vaccination and infection – key points and outstanding questions
Tick-borne Encephalitis (TBE) is a severe disease of the Central Nervous System (CNS) caused by the tick-borne encephalitis virus (TBEV). The generation of protective immunity after TBEV infection or TBE vaccination relies on the integrated responses of many distinct cell types at distinct physical locations. While long-lasting memory immune responses, in particular, form the basis for the correlates of protection against many diseases, these correlates of protection have not yet been clearly defined for TBE. This review addresses the immune control of TBEV infection and responses to TBE vaccination. Potential correlates of protection and the durability of protection against disease are discussed, along with outstanding questions in the field and possible areas for future research.
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1352720
Open AccessDefining the “Correlate(s) of Protection” to tick-borne encephalitis vaccination and infection – key points and outstanding questions
Tick-borne Encephalitis (TBE) is a severe disease of the Central Nervous System (CNS) caused by the tick-borne encephalitis virus (TBEV). The generation of protective immunity after TBEV infection or TBE vaccination relies on the integrated responses of many distinct cell types at distinct physical locations. While long-lasting memory immune responses, in particular, form the basis for the correlates of protection against many diseases, these correlates of protection have not yet been clearly defined for TBE. This review addresses the immune control of TBEV infection and responses to TBE vaccination. Potential correlates of protection and the durability of protection against disease are discussed, along with outstanding questions in the field and possible areas for future research.